Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension

@article{Behringer2015PioglitazoneAC,
  title={Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension},
  author={Arnica Behringer and Manuela Trappiel and Eva Maria Berghausen and Henrik ten Freyhaus and Ernst Wellnhofer and Margarete Odenthal and Florian Blaschke and Fikret Er and Natig Gassanov and Stephan Rosenkranz and Stephan Baldus and Kai Kappert and Evren Caglayan},
  journal={Naunyn-Schmiedeberg's Archives of Pharmacology},
  year={2015},
  volume={389},
  pages={369-379}
}
Pulmonary arterial hypertension (PAH) is a fatal disease with limited therapeutic options. Pathophysiological changes comprise obliterative vascular remodelling of small pulmonary arteries, elevated mean pulmonary arterial systolic pressure (PASP) due to elevated resistance of pulmonary vasculature, adverse right ventricular remodelling, and heart failure. Recent findings also indicate a role of increased inflammation and insulin resistance underlying the development of PAH. We hypothesized… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Similar Papers

Loading similar papers…